Markets
Wegovy...
Wegovy injection (Steve Christo/Getty Images)

Hims & Hers falls after Novo Nordisk launches discounted Wegovy for uninsured

The reduced price for Wegovy is still roughly double what compounded versions cost.

J. Edward Moreno

Hims & Hers shares fell and Novo Nordisk shares rose after the drugmaker announced Wednesday morning that it launched a telehealth platform, NovoCare, designed to give uninsured patients access to Wegovy, its blockbuster weight-loss drug.

Novo Nordisk, the Danish drugmaker that makes popular GLP-1 weight-loss drugs, said NovoCare will allow patients without insurance to access their drugs directly at almost a third of the cost it typically charges insurers. This comes after the Food and Drug Administration declared on February 21 that the shortage of semaglutide, the active ingredient in Wegovy and Ozempic, is over, ending the allowance for copycat pharmacies like Hims & Hers to sell exact copies.

Hims & Hers has said its game plan moving forward is to sell Novo Nordisk’s older, less effective GLP-1 drugs and oral medications.

NovoCare will offer Wegovy for $499 a month for patients without insurance. While that is more affordable than the upward of $1,300 Novo Nordisk charges patients with insurance, its still more than double what the compounded versions cost.

That said, Wegovy comes in individual pens that are prefilled with the patient’s dose. Compounding pharmacies typically send a vial and the patient is responsible for administering the dose. That makes Wegovy (and similar GLP-1 drugs) more costly to produce than compounded versions.

Screenshot 2025-03-05 at 9.51.19 AM
Sherwood News

Eli Lilly, which makes competing GLP-1 drugs, announced a similar platform dubbed Lilly Direct that offers its drugs to insured patients at similar price points as NovoCare. (Hims & Hers has never sold copycat versions of Eli Lillys drugs, though other compounding pharmacies have.)

Compounding pharmacies have been a pain in the side of Novo Nordisk and Eli Lilly, chipping away at the edges of their market share for GLP-1 drugs. The pharmaceutical giants have launched ad campaigns questioning the safety of compounded drugs.

More Markets

See all Markets
markets

Lucid reports Q4 earnings miss, revenue beat

Luxury EV maker Lucid reported its fourth-quarter earnings after the bell Tuesday. Shares fell more than 6% in after-hours trading.

The company posted an adjusted loss of $3.08 per share, wider than the $2.63 loss expected by analysts polled by FactSet. Lucid booked $522.7 million in revenue, beating the consensus estimate of $459.5 million.

Lucid issued a full-year 2026 production outlook of between 25,000 to 27,000 vehicles, representing 40% to 51% growth from 2025’s figures. Lucid downwardly revised its full-year 2025 production numbers from 18,378 to 17,840 vehicles due to internal validation issues.

The company maintained the timeline of its unnamed midsize SUV due to begin production later this year. That schedule puts it close to rival Rivian’s planned second-quarter release of its R2 SUV.

Lucid did not issue an update to its ongoing CEO search. The company has been led by interim CEO Marc Winterhoff for the past year, after it abruptly announced in its fourth-quarter 2024 report that then CEO Peter Rawlinson would step aside.

The stock has fallen to all-time lows this month and is down 98% from its high in 2021. Last week, the company announced it would lay off 12% of its US workforce in an effort to improve profitability.

markets

Tempus AI slides after missing Q4 EBITDA target

Cancer diagnostics company and sometimes retail shareholder favorite Tempus AI reported soft Q4 adjusted EBITDA numbers late Tuesday, sending shares lower in the after-hours session. 

It reported: 

  • Q4 revenue of $367.2 million vs. FactSet’s expectation of $362.8 million.

  • An adjusted loss per share of $0.04 vs. the $0.04 loss estimated.

  • Adjusted EBITDA of $12.9 million vs. expectations for $22 million, per FactSet.

Since going public in June 2024, Tempus has been a volatile stock that has both doubled — and cratered — on multiple occasions. That spectacle has at times captured the attention of retail traders who’ve tried to ride the waves.

Of late, the wave has been breaking bad, with shares down more than 30% since the stock hit a record high on October 8, 2025

Still, the company is now adjusted EBITDA positive. That, CEO Eric Lefkofsky told us last year, is the first milestone on Tempus journey to profitability, a mark that analysts think will take until at least next year for the company to hit.

markets

Sandisk sinks more as product release underwhelms market

Sandisk’s online event marking its one-year anniversary since being spun off from Western Digital seems to be something of a damp squib.

The shares, already down a fair bit following the Citron Research short announcement, fell further after the company announced an upgrade to its consumer solid state memory drives alongside a YouTube-based presentation aimed at highlighting all the things one might do with, well, access to additional digital storage.

The stock — which is still up more than 150% in 2026 — was down more than 7% shortly after the company’s post at 2 p.m. ET. That was in stark contrast to the bump software stocks were riding following Anthropic’s product announcement earlier on Tuesday.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.